JP2023539154A5 - - Google Patents
Info
- Publication number
- JP2023539154A5 JP2023539154A5 JP2023512354A JP2023512354A JP2023539154A5 JP 2023539154 A5 JP2023539154 A5 JP 2023539154A5 JP 2023512354 A JP2023512354 A JP 2023512354A JP 2023512354 A JP2023512354 A JP 2023512354A JP 2023539154 A5 JP2023539154 A5 JP 2023539154A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- administering
- effective amount
- intravenous solution
- solution according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2012954.0 | 2020-08-19 | ||
| GBGB2012956.5A GB202012956D0 (en) | 2020-08-19 | 2020-08-19 | Etoposide toniribate formulation |
| GB2012956.5 | 2020-08-19 | ||
| GBGB2012954.0A GB202012954D0 (en) | 2020-08-19 | 2020-08-19 | Etoposide toniribate formulation |
| PCT/EP2021/073034 WO2022038226A1 (en) | 2020-08-19 | 2021-08-19 | Etoposide toniribate formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539154A JP2023539154A (ja) | 2023-09-13 |
| JP2023539154A5 true JP2023539154A5 (https=) | 2024-08-27 |
Family
ID=80322580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512354A Pending JP2023539154A (ja) | 2020-08-19 | 2021-08-19 | エトポシドトニリベート製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230398069A1 (https=) |
| EP (1) | EP4199933A1 (https=) |
| JP (1) | JP2023539154A (https=) |
| KR (1) | KR20230131815A (https=) |
| AU (1) | AU2021327164A1 (https=) |
| CA (1) | CA3189720A1 (https=) |
| WO (1) | WO2022038226A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4233837A1 (en) * | 2022-02-24 | 2023-08-30 | CellAct Pharma GmbH | Solid and oral etoposide toniribate compositions |
| CN116983259A (zh) * | 2023-09-27 | 2023-11-03 | 成都瑞尔医药科技有限公司 | 一种依托泊苷注射液的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09507233A (ja) * | 1993-12-29 | 1997-07-22 | マトリクス ファーマスーティカル，インコーポレイティド | 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物 |
| US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| AU2002358086B2 (en) * | 2001-12-03 | 2009-06-04 | Universitatsklinikum Charite Der Humboldt-Universitat Zu Berlin Technologie Transferstelle | Podophyllotoxins as antiproliferative agents |
| JP4020256B2 (ja) * | 2003-05-23 | 2007-12-12 | 日本化薬株式会社 | 前立腺癌の局所治療剤 |
| JP2008543789A (ja) * | 2005-06-17 | 2008-12-04 | ホスピラ オーストラリア ピーティーワイ エルティーディー | ドセタキセルの液体薬学的処方物 |
| US9889147B2 (en) * | 2010-04-16 | 2018-02-13 | Cellact Pharma Gmbh | Analogues of etoposide for the treatment of tumours |
| KR102122429B1 (ko) * | 2011-04-28 | 2020-06-12 | 온코펩타이드즈 아베 | 세포독성 디펩티드의 동결건조 제제 |
| DK2701720T3 (en) * | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| GB2513299A (en) * | 2013-03-12 | 2014-10-29 | Cellact Pharma Gmbh Biomedizinzentrum | Compounds for targeting cancer stem cells |
-
2021
- 2021-08-19 KR KR1020237009044A patent/KR20230131815A/ko active Pending
- 2021-08-19 CA CA3189720A patent/CA3189720A1/en active Pending
- 2021-08-19 US US18/022,353 patent/US20230398069A1/en active Pending
- 2021-08-19 EP EP21765900.2A patent/EP4199933A1/en active Pending
- 2021-08-19 AU AU2021327164A patent/AU2021327164A1/en active Pending
- 2021-08-19 JP JP2023512354A patent/JP2023539154A/ja active Pending
- 2021-08-19 WO PCT/EP2021/073034 patent/WO2022038226A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2013155188A5 (https=) | ||
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| JP2023541432A5 (https=) | ||
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| JP2017506624A5 (https=) | ||
| JP2013541583A5 (https=) | ||
| MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| JP2020523356A5 (https=) | ||
| JP2016519107A5 (https=) | ||
| JP2023539154A5 (https=) | ||
| JP2018522028A5 (https=) | ||
| MX2017011169A (es) | Uso de citrato ferrico en el tratamiento de anemia por deficiencia de hierro. | |
| JP2022532038A5 (https=) | ||
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| JP2018516920A5 (https=) | ||
| KR20220083020A (ko) | 알츠하이머병을 동반한 혈관성 치매를 치료하는 약제학적 복합제제 | |
| RU2018107515A (ru) | Средство, снижающее интенсивность гиперактивности детрузора с нарушенной сократимостью | |
| CN104547150A (zh) | 消炎止痛外用药做为肿瘤、痈疮治疗口服剂的应用 | |
| JP2015529664A5 (https=) | ||
| JP2010519274A5 (https=) | ||
| RU2020123217A (ru) | Противо-SARS-CoV-2 вирусное средство Антипровир | |
| KR20220085094A (ko) | 알레르기성 결막염을 동반한 만성 비염을 치료하는 약제학적 복합제제 | |
| RU2018119120A (ru) | D-пролиновые производные в качестве агента, уменьшающего количество sap |